---
company: Citius Pharmaceuticals, Inc.
ticker: CTXR
form: 8-K
filed: 2026-05-15
accession: 0001213900-26-057876
source: https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/
---

# Citius Pharmaceuticals (CTXR) earnings release, May 15, 2026

Citius Pharmaceuticals, Inc. (CTXR) · Form 8-K, Item 2.02 · Filed 2026-05-15 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/)

Citius Pharmaceuticals, Inc. Reports Fiscal

Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®

Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and equity financing

Advanced patient access with payer coverage near 100% of commercial lives and 83% of LYMPHIR target accounts on formulary or in review

CRANFORD, N.J., May 15, 2026 – Citius

Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and financial results for the fiscal second quarter ended March 31, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius

Oncology, Inc. (Nasdaq: CTOR).

“The first half of fiscal 2026 demonstrated meaningful commercial progress at our majority-owned subsidiary Citius Oncology. In the four months of commercial sales since the December

2025 launch of LYMPHIR, Citius Oncology generated $5.6 million in net revenue at approximately 80% gross margins, advanced 83% of target accounts to formulary inclusion or active review, and secured payer coverage representing near 100% of covered commercial lives with no reimbursement denials reported to date. Importantly, major academic centers have begun to transition patients to local community infusion centers for treatment, a critical next phase of commercial scaling. These results reflect our efforts to build a durable patient access foundation upon which to drive growth,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.

“Subsequent to quarter end, Citius Oncology secured up to $36.5 million in combined debt and equity financing through its senior secured credit facility with Avenue Capital and the exercise of outstanding warrants, complemented by Citius Pharma’s $5 million registered direct offering. Together, these proceeds are expected to fund Citius Pharma’s activities as well as the completion of the LYMPHIR commercial field force buildout by mid-summer.

This will support expanded physician engagement and broader market penetration, positioning Citius Oncology to accelerate growth as the launch matures. We believe Citius Oncology maintains sufficient inventory to support anticipated commercial demand, as well as additional demand outside the U.S., as we begin to see orders for product through our global distribution partners.”

“Moreover, we are encouraged by positive preliminary topline Phase 1 data from two investigator-initiated combination studies, with pembrolizumab and prior to CAR-T therapy, which reinforce LYMPHIR’s potential as a platform asset in combination regimens. At the Citius Pharma level, we also remain focused on advancing Mino-Lok and Halo-Lido with the FDA and on disciplined execution of our mission to bring first-in-class therapies to patients,” concluded Mazur.

Fiscal Second Quarter 2026 Business Highlights and Subsequent Developments

Fiscal Second Quarter 2026 Financial Highlights and Subsequent Events²

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a

Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.³

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharmaceuticals. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,”

“plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our... (truncated)that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to regain compliance with Nasdaq’s continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:

Ilanit Allen ir@citiuspharma.com

908-967-6677 x113

Media Contact:

STiR-communications

Greg Salsburg

Greg@STiR-communications.com – Financial Tables Follow –⁴

## Financial statements

### Income Statement (Three Months Ended — (Unaudited))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Six Months Ended – March 31, – 2026 | Six Months Ended – March 31, – 2025 |
|---|---:|---:|---:|---:|
| Revenues | 1,667,298 | $— | 5,611,409 | $— |
| Cost of revenues | -328,878 |  | -1,118,086 |  |
| Gross Profit | 1,338,420 |  | 4,493,323 |  |
| Operating Expenses | Research and development | 1,633,518 | 3,766,525 | 3,233,237 | 5,893,563 |
| Operating Expenses | Amortization of in-process research and development | 1,720,312 |  | 2,293,750 |  |
| Operating Expenses | General and administrative | 26,391,101 | 4,792,122 | 32,111,828 | 10,179,874 |
| Operating Expenses | Stock-based compensation – general and administrative | 3,788,275 | 2,702,031 | 8,068,502 | 5,226,855 |
| Operating Expenses | Total Operating Expenses | 33,533,206 | 11,260.678 | 45,707,317 | 21,300,292 |
| Operating Expenses | Operating Loss | -32,194,786 | -11,260,678 | -41,213,994 | -21,300,292 |
| Other Income (Expense) | Interest income | 53,584 | 13,413 | 98,681 | 36,021 |
| Other Income (Expense) | Gain on sale of New Jersey net operating losses | 3,833,277 |  | 3,833,277 |  |
| Other Income (Expense) | Interest expense | -33,031 |  | -188,569 |  |
| Other Income (Expense) | Total Other Income, Net | 3,853,830 | 13,413 | 3,743,389 | 36,021 |
| Other Income (Expense) | Loss before Income Taxes | -28,340,956 | -11,247,265 | -37,470,605 | -21,264,271 |
| Other Income (Expense) | Income tax expense (benefit) | -231,210 | 264,240 | 33,030 | 528,480 |
| Other Income (Expense) | Net Loss | -28,109,746 | -11,511,505 | -37,503,635 | -21,792,751 |
| Other Income (Expense) | Net loss attributable to non-controlling interest | 6,878,606 | 595,000 | 8,051,710 | 1,108,000 |
| Other Income (Expense) | Net loss applicable to common stockholders | -21,231,140 | -10,916,505 | -29,451,925 | -20,684,751 |
| Other Income (Expense) | Net Loss Per Share - Basic and Diluted | -0.95 | -1.27 | -1.34 | -2.58 |
| Weighted Average Common Shares Outstanding | Basic and diluted (includes pre-funded warrants from the October 2025 offering) | 22,376,427 | 8,581,207 | 21,931,009 | 8,029,834 |

### Balance Sheet (September 30, — (Unaudited))

| | March 31, – 2026 | September 30, – 2025 |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 4,590,174 | 4,252,290 |
| Current Assets: | Accounts receivable, net of allowances | 1,079,055 |  |
| Current Assets: | Inventory | 22,659,590 | 22,286,693 |
| Current Assets: | Prepaid expenses | 3,356,882 | 1,395,490 |
| Current Assets: | Total Current Assets | 31,685,701 | 27,934,473 |
| Current Assets: | Operating lease right-of-use asset, net | 794,518 | 818,694 |
| Current Assets: | Deposits | 38,062 | 38,062 |
| Current Assets: | In-process research and development, net of accumulated amortization | 90,506,250 | 92,800,000 |
| Current Assets: | Deferred financing costs | 169,252 |  |
| Current Assets: | Goodwill | 9,346,796 | 9,346,796 |
| Current Assets: | Total Other Assets | 100,060,360 | 102,184,858 |
| Current Assets: | Total Assets | 132,540,579 | 130,938,025 |
| Current Liabilities: | Accounts payable | 9,453,803 | 13,693,692 |
| Current Liabilities: | License payable | 17,650,000 | 22,650,000 |
| Current Liabilities: | Accrued expenses | 24,138,264 | 4,190,253 |
| Current Liabilities: | Accrued compensation | 3,602,007 | 3,292,447 |
| Current Liabilities: | Note payable |  | 1,000,000 |
| Current Liabilities: | Operating lease liability | 171,495 | 88,348 |
| Current Liabilities: | Total Current Liabilities | 55,015,569 | 44,914,740 |
| Current Liabilities: | Deferred tax liability | 7,803,790 | 7,770,760 |
| Current Liabilities: | Operating lease liability – noncurrent | 636,667 | 724,925 |
| Current Liabilities: | Total Liabilities | 63,456,026 | 53,410,425 |
| Stockholders’ Equity: | Common stock - $0.001 par value; 250,000,000 shares authorized; 22,376,427 and 18,067,744 shares issued and outstanding at March 31, 2026 and September 30, 2025, respectively | 22,376 | 18,068 |
| Stockholders’ Equity: | Additional paid-in capital | 329,775,214 | 306,336,239 |
| Stockholders’ Equity: | Accumulated deficit | -268,256,054 | -238,804,129 |
| Stockholders’ Equity: | Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | 61,541,536 | 67,550,178 |
| Stockholders’ Equity: | Non-controlling interest | 7,543,017 | 9,977,422 |
| Stockholders’ Equity: | Total Equity | 69,084,553 | 77,527,600 |
| Stockholders’ Equity: | Total Liabilities and Equity | 132,540,579 | 130,938,025 |

### Cash Flow ((Unaudited))

| | 2026 | 2025 |
|---|---:|---:|
| Cash Flows From Operating Activities: | Net loss | -37,503,635 | -21,792,751 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation expense | 8,068,502 | 5,226,855 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Issuance of common stock for services | 107,510 |  |
| Adjustments to reconcile net loss to net cash used in operating activities: | Issuance of common stock warrant | 68,597 |  |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of in-process research and development | 2,293,750 |  |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization (accretion) of operating lease right-of-use asset | 24,176 | 110,845 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Deferred income tax expense | 33,030 | 528,480 |
| Changes in operating assets and liabilities: | Accounts receivable, net of allowances | -1,079,055 |  |
| Changes in operating assets and liabilities: | Inventory | -372,897 | -7,070,487 |
| Changes in operating assets and liabilities: | Prepaid expenses | -1,961,392 | -308,791 |
| Changes in operating assets and liabilities: | Accounts payable | -4,239,889 | 4,441,023 |
| Changes in operating assets and liabilities: | Accrued expenses | 19,948,011 | 8,762,217 |
| Changes in operating assets and liabilities: | Accrued compensation | 309,560 | 955,048 |
| Changes in operating assets and liabilities: | Operating lease liability | -5,111 | -117,767 |
